Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

SUNPHARMA NSE

Key Fundamentals

LargecapPharmaceuticalsHealthcare
Market Cap
4.5L Cr
Volatility
Moderate
P/E Ratio
37.2
EBITDA
₹19,703 Cr
Return on Equity
13.79%
Debt to Equity
0.06
Book Value
₹348.31
EPS
₹43.95
52W High
₹2,046.9
52W Low
₹1,548

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Sun Pharmaceutical Industries Ltd insights

54 extracted metrics + investor summaries across FY07–FY27.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 34.1%

Weaknesses

1
  • The company has delivered a poor sales growth of 11.8% over past five years.

Growth Rate

Revenue Growth
12.69% ↗
Net Income Growth
5.32% ↘
Cash Flow Change
-11.75% ↘
ROE
-8.98% ↘
ROCE
-5.18% ↘
EBITDA Margin (Avg.)
1.46% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 20h ago
AI opinion · based on fundamentals
Risk medium

Sun Pharmaceutical Industries is India's largest pharmaceutical company by market share (~8.4-8.5%) with a market cap of approximately ₹4.6 lakh crore, trading at a PE of 38.1x. The company delivered FY25 gross sales growth of 9% YoY with EBITDA up 17.3% and adjusted net profit up 19%, while its Global Innovative Medicines segment now accounts for over 20% of consolidated sales.

Bull Case 8
  • Dominant domestic market position with ~8.5% market share in India, the largest among all pharmaceutical companies, providing pricing power and distribution reach
  • Near debt-free balance sheet gives financial flexibility for acquisitions, R&D investment, and ability to weather downturns without leverage risk
  • FY25 EBITDA grew 17.3% YoY and adjusted net profit grew 19% YoY, demonstrating strong operating leverage and margin expansion ahead of revenue growth of 9%
  • Global Innovative Medicines (specialty) segment now accounts for over 20% of sales (22.2% in Q4FY26) and grew 20.1% in Q4FY26, providing a higher-margin revenue mix shift away from commoditized generics
  • Consistent ROE of 16% over the last 1, 3, and 5-year periods indicates disciplined capital allocation and sustained profitability
  • Healthy dividend payout ratio of 34.1% with a current dividend yield of 0.83%, reflecting shareholder-friendly capital return policy
  • Ilumya (tildrakizumab) franchise expanding into new indications — psoriatic arthritis sBLA accepted by US FDA in March 2026, and nail psoriasis approval in December 2025, extending the product lifecycle
  • Stock CAGR of 20% over 5 years and 19% over 3 years reflects consistent re-rating driven by specialty business transition
Bear Case 8
  • PE ratio of 38.1x is elevated for a pharma company with only 11% TTM sales growth, implying the stock is priced for significant future acceleration that may not materialize
  • Compounded sales growth of just 12% over 5 years and 7% over 10 years indicates structurally modest top-line expansion for a company of this valuation
  • TTM profit growth has decelerated to 10% from 13% CAGR over 3 years and 17% over 5 years, suggesting margin expansion tailwinds may be fading
  • Price-to-book ratio of 5.53x is rich relative to the 16% ROE, implying limited margin of safety if growth disappoints
  • US generics business faces continued pricing pressure and competition, while specialty success with Ilumya depends on execution against well-funded biologic competitors in dermatology
  • Dividend yield of only 0.83% provides minimal income cushion for investors if capital appreciation slows from the current elevated valuation
  • 10-year stock CAGR of only 9% versus 20% over 5 years suggests that long-term compounding has been uneven, with periods of significant underperformance
  • Q2FY26 net profit growth slowed to just 2.6% YoY, raising questions about sustainability of the earnings momentum that drove re-rating

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 20h ago
Headwinds 2
  • US sales down 10% YoY Jul 31

    Q1 US sales fell to USD 427M from USD 473M YoY, a 10% decline. Revenue of ₹153B missed the ₹156.25B estimate and EBITDA margin contracted to 28.9% from 31.06% YoY.

  • Q1 net profit misses estimate Jul 31

    Net profit of ₹29B came in below the ₹30.5B consensus estimate despite rising from ₹23B YoY.

Positives 4
  • Brazil semaglutide approval won Jul 29

    Sun Pharma secured ANVISA approval to manufacture and market semaglutide for type 2 diabetes in Brazil's USD 413M market, with partner Hypera Pharma planning rapid launch.

  • US Lipitor antitrust case dismissed Aug 17

    US Third Circuit Court of Appeals affirmed summary judgment in Sun Pharma's favor, dismissing class certification and closing the long-standing Lipitor antitrust litigation.

  • Nidlegy EMA resubmission filed Jul 28

    Partner Philogen resubmitted the MAA for Nidlegy to EMA on Jul 27 with 33-month follow-up data from Phase III PIVOTAL study for melanoma treatment, with supporting data accepted for JCO publication.

  • All AGM resolutions passed Aug 1

    All resolutions at Sun Pharma's 34th AGM on July 31, 2026, were passed with requisite majority, confirming full shareholder approval.

Neutral 4
  • Large institutional block trades Jul 27

    Multiple block trades totalling over ₹749 crores occurred between Jul 27 and Aug 3 at prices ranging from ₹1952.60 to ₹1982.60 per share, reflecting significant institutional activity.

  • Promoters reclassified to public Aug 6

    NSE and BSE issued no-objection letters for reclassifying Krishna, Sudhir, and Raksha Valia from promoter group to public category.

  • Investor meetings scheduled Aug 2026 Aug 5

    Sun Pharma announced analyst and institutional investor meetings in Mumbai during August 2026 with Nirmal Bang, Emkay, and Equirus.

  • Q1FY27 results filed Aug 1

    Unaudited financial results for Q1 ended June 30, 2026 were filed with exchanges, with newspaper advertisements published on August 1.

TL;DR: Sun Pharma delivered YoY profit growth in Q1 but missed Street estimates on both revenue and net profit, with US sales declining 10%. On the growth front, Brazil semaglutide approval and the Nidlegy EMA resubmission open new revenue avenues, while the Lipitor litigation closure removes a legal overhang. The key risk remains US business weakness; the trend is mixed with emerging market expansion partially offsetting developed market softness.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
11,941
12,192
12,381
11,983
12,653
13,291
13,675
12,959
13,851
14,478
15,521
14,612
15,300
Expenses
8,609
9,013
8,904
8,948
9,045
9,352
9,666
9,243
9,550
9,951
10,572
10,658
10,882
Operating Profit
3,332
3,179
3,477
3,035
3,608
3,939
4,009
3,716
4,302
4,527
4,948
3,954
4,418
OPM %
28%
26%
28%
25%
29%
30%
29%
29%
31%
31%
32%
27%
29%
Other Income
-118
294
180
504
533
354
149
251
-354
470
89
458
520
Interest
81
49
35
74
62
69
52
49
75
100
78
86
100
Depreciation
651
633
622
650
655
626
631
664
701
730
732
775
739
PBT
2,481
2,791
3,000
2,816
3,424
3,598
3,476
3,254
3,173
4,168
4,227
3,551
4,099
Tax %
19%
14%
14%
5%
16%
16%
16%
34%
27%
25%
20%
23%
29%
Net Profit
2,006
2,385
2,561
2,659
2,861
3,037
2,913
2,154
2,293
3,125
3,381
2,710
2,901
EPS in Rs
8.43
9.9
10.52
11.06
11.82
12.67
12.1
8.96
9.5
13
14.04
11.31
12.06
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
27,392
28,487
31,578
26,489
29,066
32,838
33,498
38,654
43,886
48,497
52,578
58,462
59,911
Expenses
19,498
20,313
21,476
20,858
22,689
25,855
25,028
28,397
32,235
35,479
37,464
41,961
42,063
Operating Profit
7,894
8,174
10,102
5,631
6,377
6,983
8,470
10,258
11,650
13,018
15,114
16,501
17,847
OPM %
29%
29%
32%
21%
22%
21%
25%
27%
27%
27%
29%
28%
30%
Other Income
283
-42
610
-135
-258
382
-3,449
-3,505
459
865
1,444
1,895
1,537
Interest
579
523
400
518
555
303
141
127
172
238
231
339
364
Depreciation
1,195
1,038
1,265
1,500
1,753
2,053
2,080
2,144
2,529
2,557
2,575
2,938
2,976
PBT
6,403
6,571
9,048
3,479
3,810
5,010
2,799
4,481
9,408
11,088
13,752
15,119
16,045
Tax %
14%
14%
13%
26%
16%
16%
18%
24%
9%
13%
20%
24%
—
Net Profit
5,476
5,658
7,846
2,542
3,208
4,172
2,272
3,389
8,513
9,610
10,965
11,509
12,117
EPS in Rs
21.92
18.89
29.03
8.73
11.11
15.69
12.1
13.64
35.32
39.91
45.55
47.84
50.41
Div. Payout %
14%
5%
12%
23%
25%
25%
62%
73%
33%
34%
35%
33%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
207
241
240
240
240
240
240
240
240
240
240
240
Reserves
25,431
32,742
36,400
38,074
41,169
45,025
46,223
47,771
55,755
63,427
71,978
83,330
Borrowings
8,996
8,497
9,832
10,385
10,514
8,315
3,869
1,290
6,886
3,274
2,362
4,627
Other Liabilities
14,089
13,948
14,624
15,598
12,666
14,615
17,291
20,474
17,831
18,387
17,328
20,210
Total Liabilities
48,723
55,428
61,095
64,297
64,590
68,194
67,622
69,776
80,712
85,328
91,908
1,08,407
Fixed Assets
12,682
15,872
17,675
18,853
21,837
22,847
21,553
22,665
24,065
23,248
22,586
32,822
CWIP
2,039
2,175
2,801
2,465
1,411
1,220
1,567
1,287
4,973
5,354
6,644
3,052
Investments
2,716
1,830
1,192
7,143
7,903
10,143
9,612
12,849
14,824
15,026
18,354
24,723
Other Assets
31,286
35,550
39,427
35,837
33,439
33,984
34,890
32,975
36,849
41,700
44,324
47,811
Total Assets
48,723
55,428
61,095
64,297
64,590
68,194
67,622
69,776
80,712
85,328
91,908
1,08,407
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
5,616
6,686
7,082
3,907
2,196
6,555
6,170
8,985
4,959
12,135
14,072
12,419
Investing
-1,502
-3,949
-4,186
-3,104
-310
-2,225
407
-5,556
-7,220
-763
-5,183
-10,405
Financing
-1,187
-1,889
-2,285
-1,539
-2,731
-5,715
-5,980
-5,193
2,376
-6,710
-7,906
-2,513
Net Cash Flow
2,927
848
611
-736
-844
-1,386
596
-1,765
115
4,662
983
-498
Free Cash Flow
3,316
3,353
3,492
2,013
-966
5,105
5,097
7,550
2,895
9,964
12,005
8,906
CFO/OP
93
106
90
83
48
113
85
78
56
105
96
89
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
68
87
83
108
112
105
99
99
95
85
91
97
Inventory Days
307
370
307
338
366
311
378
315
360
338
348
363
Days Payable
178
207
197
234
192
142
167
158
194
194
210
232
Cash Conversion Cycle
197
251
193
212
285
274
310
255
261
229
228
228
Working Capital Days
-7
37
-4
-31
31
51
51
47
40
55
65
54
ROCE %
23%
18%
20%
10%
10%
10%
13%
17%
16%
17%
20%
21%

Shareholding Pattern

As of Jun 2026
Promoters 54.48%
DIIs 22.18%
FIIs 14.53%
Public 5.48%
Others 3.33%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
16.79%
0.00%
17.72%
17.23%
18.02%
18.05%
17.96%
17.26%
16.55%
16.12%
15.93%
14.53%
DIIs
21.59%
21.93%
21.67%
20.94%
19.94%
19.57%
18.60%
19.14%
19.24%
19.75%
19.67%
17.97%
18.83%
19.28%
18.61%
18.55%
18.70%
19.50%
20.24%
20.82%
21.11%
22.18%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
7.34%
7.21%
6.79%
6.68%
6.49%
6.31%
5.91%
5.76%
5.70%
5.65%
5.56%
5.41%
5.44%
5.57%
5.43%
5.47%
5.42%
5.35%
5.53%
5.40%
5.30%
5.48%
Others
16.60%
16.38%
17.05%
17.90%
19.09%
19.64%
21.01%
20.63%
20.58%
20.12%
3.51%
22.13%
3.53%
3.44%
3.46%
3.46%
3.45%
3.42%
3.20%
3.18%
3.18%
3.33%
No. of Shareholders
0
7,09,045
7,57,366
6,75,908
6,80,800
6,62,384
6,47,167
6,43,512
6,25,252
6,24,561
6,16,588
6,12,626
6,31,392
6,73,217
6,57,317
6,89,623
7,04,983
7,23,770
7,43,877
7,10,900
6,90,957
7,10,246

Documents

Frequently Asked Questions about Sun Pharmaceutical Industries Ltd

What does Sun Pharmaceutical Industries Ltd do?
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading...
Where is Sun Pharmaceutical Industries Ltd (SUNPHARMA) listed?
Sun Pharmaceutical Industries Ltd is listed on the Indian stock exchanges. It is listed on NSE: SUNPHARMA and BSE: 524715. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Sun Pharmaceutical Industries Ltd belong to?
Sun Pharmaceutical Industries Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd has a market capitalisation of approximately ₹454170.12 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Sun Pharmaceutical Industries Ltd?
The Price-to-Earnings (PE) ratio of Sun Pharmaceutical Industries Ltd is 37.20. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Sun Pharmaceutical Industries Ltd?
Over the past 52 weeks, Sun Pharmaceutical Industries Ltd has traded between a low of ₹1,548 and a high of ₹2,046.9. This range helps investors understand the stock's price volatility and recent trading levels.
Does Sun Pharmaceutical Industries Ltd pay dividends?
Yes, Sun Pharmaceutical Industries Ltd has a dividend yield of 0.85%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd has a Return on Equity (ROE) of 13.79%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Sun Pharmaceutical Industries Ltd on Tapetide?
On Tapetide, you can view Sun Pharmaceutical Industries Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]

Website sunpharma.com
CEO Mr. Dilip Shantilal Shanghvi
Employees 43,000
Listed 1995-02-08
Face Value ₹ 1
Issued Size 2,39,93,34,970

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List